MDS 2021 | Research focuses in atypical parkinsonism
Irene Litvan, MD, FAAN, FANA, University of California San Diego, La Jolla, CA, shares an overview of key research themes under investigation in the field of atypical parkinsonism. Strategies to enable earlier diagnosis is one such focus. Developing novel diagnostic biomarkers, bringing the latest science into clinical practice, and educating health care professionals about atypical parkinsonism are important steps to achieving earlier diagnosis. Dr Litvan also discusses the clear need for new therapeutic agents and specific outcome measures. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.
Disclosures
Dr. Litvan’s research is supported by the National Institutes of Health grants: 2R01AG038791-06A, U01NS100610, U01NS80818, R25NS098999; U19 AG063911-1 and 1R21NS114764-01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, Biohaven Pharmaceuticals, Novartis, Brain Neurotherapy Bio and United Biopharma SRL – UCB. She was a member of the Scientific Advisory Board of Lundbeck and is a Scientific advisor for Amydis and Rossy Center for Progressive Supranuclear Palsy University of Toronto. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology.
